1209 IMO-2125 PLUS RIBAVIRIN GIVES SUBSTANTIAL FIRST-DOSE VIRAL LOAD REDUCTIONS, CUMULATIVE ANTI-VIRAL EFFECT, IS WELL TOLERATED IN NAIVE GENOTYPE1 HCV PATIENTS: A PHASE 1 TRIAL

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Hepatology

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(11)61211-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases

  2013cites this paper
• Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist.

  2013cites this paper
• Toll-like receptor agonists for nonresponders to HCV treatment: hope versus promise?

  2013cites this paper
• Regulators of innate immunity as novel targets for panviral therapeutics

  2012cites this paper